麻豆原创 Analysis and Insights: Global Sympathomimetic Agents 麻豆原创
The global Sympathomimetic Agents market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Sympathomimetic Agents market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Sympathomimetic Agents, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Sympathomimetic Agents, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Sympathomimetic Agents revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Sympathomimetic Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Sympathomimetic Agents revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Pfizer
Sanofi
Novartis
Sterimax
Bedford Pharmaceuticals
Teva
Amneal Biosciences
Baxter Laboratories
Hikma Pharmaceuticals
Amphastar Pharmaceuticals
Marathon Pharmaceuticals
Bausch Health Companies
Sterling-Winthrop
Cipla USA
Nexus Pharmaceuticals
Mylan
Impax
ALK Abello
Lincoln Medical
Amphastar
Emerade
Grand Pharma
Harvest Pharmaceuticals
Merit Pharmaceutical
Tianjin Jinyao Group
Segment by Type
Dobutamine
Dopamine
Ephedrine
Epinephrine
Isoproterenol
Mephentermine
Metaraminol
Methoxamine
Norepinephrine
Phenylephrine
Segment by Application
Anaphylaxis
Cardiac Arrest
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Sympathomimetic Agents in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sympathomimetic Agents companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sympathomimetic Agents revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Sympathomimetic Agents 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Dobutamine
1.2.3 Dopamine
1.2.4 Ephedrine
1.2.5 Epinephrine
1.2.6 Isoproterenol
1.2.7 Mephentermine
1.2.8 Metaraminol
1.2.9 Methoxamine
1.2.10 Norepinephrine
1.2.11 Phenylephrine
1.3 麻豆原创 by Application
1.3.1 Global Sympathomimetic Agents 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Anaphylaxis
1.3.3 Cardiac Arrest
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sympathomimetic Agents 麻豆原创 Perspective (2019-2030)
2.2 Global Sympathomimetic Agents Growth Trends by Region
2.2.1 Sympathomimetic Agents 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sympathomimetic Agents Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Sympathomimetic Agents Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Sympathomimetic Agents 麻豆原创 Dynamics
2.3.1 Sympathomimetic Agents Industry Trends
2.3.2 Sympathomimetic Agents 麻豆原创 Drivers
2.3.3 Sympathomimetic Agents 麻豆原创 Challenges
2.3.4 Sympathomimetic Agents 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Sympathomimetic Agents by Players
3.1.1 Global Sympathomimetic Agents Revenue by Players (2019-2024)
3.1.2 Global Sympathomimetic Agents Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Sympathomimetic Agents 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Sympathomimetic Agents, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Sympathomimetic Agents 麻豆原创 Concentration Ratio
3.4.1 Global Sympathomimetic Agents 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sympathomimetic Agents Revenue in 2023
3.5 Global Key Players of Sympathomimetic Agents Head office and Area Served
3.6 Global Key Players of Sympathomimetic Agents, Product and Application
3.7 Global Key Players of Sympathomimetic Agents, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Sympathomimetic Agents Breakdown Data by Type
4.1 Global Sympathomimetic Agents Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Sympathomimetic Agents Forecasted 麻豆原创 Size by Type (2025-2030)
5 Sympathomimetic Agents Breakdown Data by Application
5.1 Global Sympathomimetic Agents Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Sympathomimetic Agents Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Sympathomimetic Agents 麻豆原创 Size (2019-2030)
6.2 North America Sympathomimetic Agents 麻豆原创 Size by Type
6.2.1 North America Sympathomimetic Agents 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Sympathomimetic Agents 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Sympathomimetic Agents 麻豆原创 Share by Type (2019-2030)
6.3 North America Sympathomimetic Agents 麻豆原创 Size by Application
6.3.1 North America Sympathomimetic Agents 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Sympathomimetic Agents 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Sympathomimetic Agents 麻豆原创 Share by Application (2019-2030)
6.4 North America Sympathomimetic Agents 麻豆原创 Size by Country
6.4.1 North America Sympathomimetic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Sympathomimetic Agents 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Sympathomimetic Agents 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Sympathomimetic Agents 麻豆原创 Size (2019-2030)
7.2 Europe Sympathomimetic Agents 麻豆原创 Size by Type
7.2.1 Europe Sympathomimetic Agents 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Sympathomimetic Agents 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Sympathomimetic Agents 麻豆原创 Share by Type (2019-2030)
7.3 Europe Sympathomimetic Agents 麻豆原创 Size by Application
7.3.1 Europe Sympathomimetic Agents 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Sympathomimetic Agents 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Sympathomimetic Agents 麻豆原创 Share by Application (2019-2030)
7.4 Europe Sympathomimetic Agents 麻豆原创 Size by Country
7.4.1 Europe Sympathomimetic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Sympathomimetic Agents 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Sympathomimetic Agents 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Sympathomimetic Agents 麻豆原创 Size (2019-2030)
8.2 China Sympathomimetic Agents 麻豆原创 Size by Type
8.2.1 China Sympathomimetic Agents 麻豆原创 Size by Type (2019-2024)
8.2.2 China Sympathomimetic Agents 麻豆原创 Size by Type (2025-2030)
8.2.3 China Sympathomimetic Agents 麻豆原创 Share by Type (2019-2030)
8.3 China Sympathomimetic Agents 麻豆原创 Size by Application
8.3.1 China Sympathomimetic Agents 麻豆原创 Size by Application (2019-2024)
8.3.2 China Sympathomimetic Agents 麻豆原创 Size by Application (2025-2030)
8.3.3 China Sympathomimetic Agents 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Sympathomimetic Agents 麻豆原创 Size (2019-2030)
9.2 Asia Sympathomimetic Agents 麻豆原创 Size by Type
9.2.1 Asia Sympathomimetic Agents 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Sympathomimetic Agents 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Sympathomimetic Agents 麻豆原创 Share by Type (2019-2030)
9.3 Asia Sympathomimetic Agents 麻豆原创 Size by Application
9.3.1 Asia Sympathomimetic Agents 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Sympathomimetic Agents 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Sympathomimetic Agents 麻豆原创 Share by Application (2019-2030)
9.4 Asia Sympathomimetic Agents 麻豆原创 Size by Region
9.4.1 Asia Sympathomimetic Agents 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Sympathomimetic Agents 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Sympathomimetic Agents 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Sympathomimetic Agents 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Sympathomimetic Agents Introduction
11.1.4 Pfizer Revenue in Sympathomimetic Agents Business (2019-2024)
11.1.5 Pfizer Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Sympathomimetic Agents Introduction
11.2.4 Sanofi Revenue in Sympathomimetic Agents Business (2019-2024)
11.2.5 Sanofi Recent Developments
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Sympathomimetic Agents Introduction
11.3.4 Novartis Revenue in Sympathomimetic Agents Business (2019-2024)
11.3.5 Novartis Recent Developments
11.4 Sterimax
11.4.1 Sterimax Company Details
11.4.2 Sterimax Business Overview
11.4.3 Sterimax Sympathomimetic Agents Introduction
11.4.4 Sterimax Revenue in Sympathomimetic Agents Business (2019-2024)
11.4.5 Sterimax Recent Developments
11.5 Bedford Pharmaceuticals
11.5.1 Bedford Pharmaceuticals Company Details
11.5.2 Bedford Pharmaceuticals Business Overview
11.5.3 Bedford Pharmaceuticals Sympathomimetic Agents Introduction
11.5.4 Bedford Pharmaceuticals Revenue in Sympathomimetic Agents Business (2019-2024)
11.5.5 Bedford Pharmaceuticals Recent Developments
11.6 Teva
11.6.1 Teva Company Details
11.6.2 Teva Business Overview
11.6.3 Teva Sympathomimetic Agents Introduction
11.6.4 Teva Revenue in Sympathomimetic Agents Business (2019-2024)
11.6.5 Teva Recent Developments
11.7 Amneal Biosciences
11.7.1 Amneal Biosciences Company Details
11.7.2 Amneal Biosciences Business Overview
11.7.3 Amneal Biosciences Sympathomimetic Agents Introduction
11.7.4 Amneal Biosciences Revenue in Sympathomimetic Agents Business (2019-2024)
11.7.5 Amneal Biosciences Recent Developments
11.8 Baxter Laboratories
11.8.1 Baxter Laboratories Company Details
11.8.2 Baxter Laboratories Business Overview
11.8.3 Baxter Laboratories Sympathomimetic Agents Introduction
11.8.4 Baxter Laboratories Revenue in Sympathomimetic Agents Business (2019-2024)
11.8.5 Baxter Laboratories Recent Developments
11.9 Hikma Pharmaceuticals
11.9.1 Hikma Pharmaceuticals Company Details
11.9.2 Hikma Pharmaceuticals Business Overview
11.9.3 Hikma Pharmaceuticals Sympathomimetic Agents Introduction
11.9.4 Hikma Pharmaceuticals Revenue in Sympathomimetic Agents Business (2019-2024)
11.9.5 Hikma Pharmaceuticals Recent Developments
11.10 Amphastar Pharmaceuticals
11.10.1 Amphastar Pharmaceuticals Company Details
11.10.2 Amphastar Pharmaceuticals Business Overview
11.10.3 Amphastar Pharmaceuticals Sympathomimetic Agents Introduction
11.10.4 Amphastar Pharmaceuticals Revenue in Sympathomimetic Agents Business (2019-2024)
11.10.5 Amphastar Pharmaceuticals Recent Developments
11.11 Marathon Pharmaceuticals
11.11.1 Marathon Pharmaceuticals Company Details
11.11.2 Marathon Pharmaceuticals Business Overview
11.11.3 Marathon Pharmaceuticals Sympathomimetic Agents Introduction
11.11.4 Marathon Pharmaceuticals Revenue in Sympathomimetic Agents Business (2019-2024)
11.11.5 Marathon Pharmaceuticals Recent Developments
11.12 Bausch Health Companies
11.12.1 Bausch Health Companies Company Details
11.12.2 Bausch Health Companies Business Overview
11.12.3 Bausch Health Companies Sympathomimetic Agents Introduction
11.12.4 Bausch Health Companies Revenue in Sympathomimetic Agents Business (2019-2024)
11.12.5 Bausch Health Companies Recent Developments
11.13 Sterling-Winthrop
11.13.1 Sterling-Winthrop Company Details
11.13.2 Sterling-Winthrop Business Overview
11.13.3 Sterling-Winthrop Sympathomimetic Agents Introduction
11.13.4 Sterling-Winthrop Revenue in Sympathomimetic Agents Business (2019-2024)
11.13.5 Sterling-Winthrop Recent Developments
11.14 Cipla USA
11.14.1 Cipla USA Company Details
11.14.2 Cipla USA Business Overview
11.14.3 Cipla USA Sympathomimetic Agents Introduction
11.14.4 Cipla USA Revenue in Sympathomimetic Agents Business (2019-2024)
11.14.5 Cipla USA Recent Developments
11.15 Nexus Pharmaceuticals
11.15.1 Nexus Pharmaceuticals Company Details
11.15.2 Nexus Pharmaceuticals Business Overview
11.15.3 Nexus Pharmaceuticals Sympathomimetic Agents Introduction
11.15.4 Nexus Pharmaceuticals Revenue in Sympathomimetic Agents Business (2019-2024)
11.15.5 Nexus Pharmaceuticals Recent Developments
11.16 Mylan
11.16.1 Mylan Company Details
11.16.2 Mylan Business Overview
11.16.3 Mylan Sympathomimetic Agents Introduction
11.16.4 Mylan Revenue in Sympathomimetic Agents Business (2019-2024)
11.16.5 Mylan Recent Developments
11.17 Impax
11.17.1 Impax Company Details
11.17.2 Impax Business Overview
11.17.3 Impax Sympathomimetic Agents Introduction
11.17.4 Impax Revenue in Sympathomimetic Agents Business (2019-2024)
11.17.5 Impax Recent Developments
11.18 ALK Abello
11.18.1 ALK Abello Company Details
11.18.2 ALK Abello Business Overview
11.18.3 ALK Abello Sympathomimetic Agents Introduction
11.18.4 ALK Abello Revenue in Sympathomimetic Agents Business (2019-2024)
11.18.5 ALK Abello Recent Developments
11.19 Lincoln Medical
11.19.1 Lincoln Medical Company Details
11.19.2 Lincoln Medical Business Overview
11.19.3 Lincoln Medical Sympathomimetic Agents Introduction
11.19.4 Lincoln Medical Revenue in Sympathomimetic Agents Business (2019-2024)
11.19.5 Lincoln Medical Recent Developments
11.20 Amphastar
11.20.1 Amphastar Company Details
11.20.2 Amphastar Business Overview
11.20.3 Amphastar Sympathomimetic Agents Introduction
11.20.4 Amphastar Revenue in Sympathomimetic Agents Business (2019-2024)
11.20.5 Amphastar Recent Developments
11.21 Emerade
11.21.1 Emerade Company Details
11.21.2 Emerade Business Overview
11.21.3 Emerade Sympathomimetic Agents Introduction
11.21.4 Emerade Revenue in Sympathomimetic Agents Business (2019-2024)
11.21.5 Emerade Recent Developments
11.22 Grand Pharma
11.22.1 Grand Pharma Company Details
11.22.2 Grand Pharma Business Overview
11.22.3 Grand Pharma Sympathomimetic Agents Introduction
11.22.4 Grand Pharma Revenue in Sympathomimetic Agents Business (2019-2024)
11.22.5 Grand Pharma Recent Developments
11.23 Harvest Pharmaceuticals
11.23.1 Harvest Pharmaceuticals Company Details
11.23.2 Harvest Pharmaceuticals Business Overview
11.23.3 Harvest Pharmaceuticals Sympathomimetic Agents Introduction
11.23.4 Harvest Pharmaceuticals Revenue in Sympathomimetic Agents Business (2019-2024)
11.23.5 Harvest Pharmaceuticals Recent Developments
11.24 Merit Pharmaceutical
11.24.1 Merit Pharmaceutical Company Details
11.24.2 Merit Pharmaceutical Business Overview
11.24.3 Merit Pharmaceutical Sympathomimetic Agents Introduction
11.24.4 Merit Pharmaceutical Revenue in Sympathomimetic Agents Business (2019-2024)
11.24.5 Merit Pharmaceutical Recent Developments
11.25 Tianjin Jinyao Group
11.25.1 Tianjin Jinyao Group Company Details
11.25.2 Tianjin Jinyao Group Business Overview
11.25.3 Tianjin Jinyao Group Sympathomimetic Agents Introduction
11.25.4 Tianjin Jinyao Group Revenue in Sympathomimetic Agents Business (2019-2024)
11.25.5 Tianjin Jinyao Group Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Pfizer
Sanofi
Novartis
Sterimax
Bedford Pharmaceuticals
Teva
Amneal Biosciences
Baxter Laboratories
Hikma Pharmaceuticals
Amphastar Pharmaceuticals
Marathon Pharmaceuticals
Bausch Health Companies
Sterling-Winthrop
Cipla USA
Nexus Pharmaceuticals
Mylan
Impax
ALK Abello
Lincoln Medical
Amphastar
Emerade
Grand Pharma
Harvest Pharmaceuticals
Merit Pharmaceutical
Tianjin Jinyao Group
听
听
*If Applicable.
